OCT Angiography in Vitreo and Chorioretinal Pathologies
December 28, 2017 updated by: Pieter Nelis, CRG UZ Brussel
Optical Coherence Tomography Angiography in Vitreo and Chorioretinal Pathologies Under the Influence of Dark and Light Adaptation
In many diseases of the vitreo and chorioretinal complex, perfusion changes have a diagnostic, prognostic or causative role.
The visualisation of perfusion was limited to invasive techniques, which were only to depict vasculature in one plane.
Optical coherence tomography is able to visualise and quantify eye perfusion layer-specific and non-invasive.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with pathology in vitreo and chorioretinal complex and age matched controls
Description
Inclusion Criteria:
- Patient with vitreo and chorioretinal pathology, aged-adapted controls
Exclusion Criteria:
- Minors, concomitant ocular pathologies, pregnancy, contra-indication for tropicamide
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Controls
|
Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
|
|
Patients
|
Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vessel density
Time Frame: 5 minutes after intervention ends
|
Vessel density measurements of macula and optic nerve
|
5 minutes after intervention ends
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2018
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
March 1, 2019
Study Registration Dates
First Submitted
December 28, 2017
First Submitted That Met QC Criteria
December 28, 2017
First Posted (Actual)
January 4, 2018
Study Record Updates
Last Update Posted (Actual)
January 4, 2018
Last Update Submitted That Met QC Criteria
December 28, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- 2812201748151
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.